Cargando…

1258. Activity of a Series of Investigational Compounds Tested Against Invasive Fungal Isolates

BACKGROUND: Fox Chase Chemical Diversity Center (FCC) is developing non-peptide analogs of host defense proteins for the treatment of invasive fungal infections mainly caused by Candida (CAN) and Aspergillus (ASP). We evaluated the activity of 6 novel compounds and 2 comparators against 150 isolates...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rhomberg, Paul R, Messer, Shawn A, Scott, Richard W, Baugh, Simon D P, Pfaller, Michael A, Castanheira, Mariana, Carvalhaes, Cecilia G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776457/ http://dx.doi.org/10.1093/ofid/ofaa439.1442

Ejemplares similares

Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates (SENTRY Program, 2016 to 2018)
por: Pfaller, Michael A., et al.
Publicado: (2020)

2115. Activity of a Long-Acting Echinocandin Rezafungin and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates: SENTRY 2018
por: Pfaller, Michael A, et al.
Publicado: (2019)

Antifungal susceptibilities of opportunistic filamentous fungal pathogens from the Asia and Western Pacific Region: data from the SENTRY Antifungal Surveillance Program (2011–2019)
por: Pfaller, Michael A., et al.
Publicado: (2021)

Correction: Antifungal susceptibilities of opportunistic filamentous fungal pathogens from the Asia and Western Pacific Region: data from the SENTRY Antifungal Surveillance Program (2011–2019)
por: Pfaller, Michael A., et al.
Publicado: (2021)

2400. Activity of a Long-Acting Echinocandin, Rezafungin, Tested Against Invasive Fungal Isolates Collected Worldwide
por: Pfaller, Michael A, et al.
Publicado: (2018)

Impact of COVID-19 on the antifungal susceptibility profiles of isolates collected in a global surveillance program that monitors invasive fungal infections
por: Pfaller, Michael A, et al.
Publicado: (2022)

Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program
por: Pfaller, Michael A., et al.
Publicado: (2017)

1454 Antifungal Susceptibility Patterns of a Global Collection of Fungal Isolates and Polysorbate-80 Effect on the Susceptibility of the Antifungal Classes
por: Castanheira, Mariana, et al.
Publicado: (2014)

347. Azole Activity against Filamentous Fungi Causing Invasive Infections in Patients from ICU and Non-ICU Units (2017-2021)
por: Carvalhaes, Cecilia G, et al.
Publicado: (2022)

Comparative activity of posaconazole and systemic azole agents against clinical isolates of filamentous fungi from a global surveillance programme
por: Carvalhaes, Cecilia G, et al.
Publicado: (2021)

868. In Vitro Activity of Isavuconazole and Other Mould-Active Triazoles Against Aspergillus fumigatus With and Without cyp51 Alterations
por: Pfaller, Michael A, et al.
Publicado: (2022)

Antifungal Activity of Isavuconazole and Comparator Agents against Contemporaneous Mucorales Isolates from USA, Europe, and Asia-Pacific
por: Carvalhaes, Cecilia G., et al.
Publicado: (2023)

1260. Activity of Manogepix (APX001A) against 2,669 Fungal Isolates from the SENTRY Surveillance Program (2018-2019) Stratified by Infection Type
por: Huband, Michael D, et al.
Publicado: (2020)

2115. Rezafungin Activity against Invasive Candidiasis Isolates Globally: Results from the 2022 Rezafungin Surveillance Program
por: Carvalhaes, Cecilia G, et al.
Publicado: (2023)

Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates
por: Pfaller, Michael A., et al.
Publicado: (2016)

1547. Activity of Tedizolid and Comparator Agents against Gram-Positive Bacterial Isolates Causing Skin and Skin Structure Infections in Pediatric Patients during 2015-2019 in the US
por: Carvalhaes, Cecilia G, et al.
Publicado: (2020)

1731. Rezafungin Activity against Candida spp. and Aspergillus spp. Isolates Causing Invasive Infections Worldwide in 2021
por: Carvalhaes, Cecilia G, et al.
Publicado: (2022)

In Vitro Activity of Isavuconazole and Other Mould-Active Azoles against Aspergillus fumigatus with and without CYP51 Alterations
por: Pfaller, Michael A., et al.
Publicado: (2023)

2043. In Vitro Activity of Manogepix Against 2,810 Fungal Isolates from the SENTRY Surveillance Program (2020-2021) Stratified by Infection Type
por: Huband, Michael D, et al.
Publicado: (2022)

2114. Evaluation of Isavuconazole Activity against Non-fumigatus Aspergillus and cryptic Aspergillus species Causing Invasive Infections Worldwide
por: Carvalhaes, Cecilia G, et al.
Publicado: (2023)

2113. Evaluation of Isavuconazole Activity against Aspergillus fumigatus Causing Invasive Infections Worldwide Using the New CLSI Clinical Breakpoints
por: Carvalhaes, Cecilia G, et al.
Publicado: (2023)

1948. Rise of Candida auris Infections Worldwide and Trends on the Activity of Fosmanogepix and Comparator Agents against C. auris Causing Invasive Infections
por: Carvalhaes, Cecilia G, et al.
Publicado: (2023)

Activities of Manogepix and Comparators against 1,435 Recent Fungal Isolates Collected during an International Surveillance Program (2020)
por: Pfaller, M. A., et al.
Publicado: (2022)

1947. Activity of Rezafungin against Echinocandin–Non-wild type C. glabrata Clinical Isolates from the Rezafungin Surveillance Program (2014–2021)
por: Carvalhaes, Cecilia G, et al.
Publicado: (2023)

568. Evaluation of the VITEK 2 XL Antimicrobial Susceptibility Testing for Non-fermenter Gram-Negative Bacilli: The Importance of Continuing to Monitor AST Systems
por: Carvalhaes, Cecilia G, et al.
Publicado: (2023)

217. Antimicrobial Activity of Dalbavancin against Gram-Positive Bacteria Isolated from Patients Hospitalized with Bacteremia in United States and European Medical Centers: Results from the International Dalbavancin Evaluation of Activity (IDEA) Program (2018-202)
por: Sader, Helio S, et al.
Publicado: (2021)

333. Tedizolid Activity against Gram-Positive Bacterial Isolates Causing Bone and Joint Infections in the United States (2015–2019)
por: Carvalhaes, Cecilia G, et al.
Publicado: (2020)

In Vitro Activity of Isavuconazole against Opportunistic Fungal Pathogens from Two Mycology Reference Laboratories
por: Pfaller, Michael A., et al.
Publicado: (2018)

1305. Antimicrobial Activity of Ceftaroline and Comparator Agents against Ceftriaxone-Non-Susceptible Streptococcus pneumoniae from the United States (2008-2020)
por: Sader, Helio S, et al.
Publicado: (2021)

1261. Antimicrobial Activity of Aztreonam-Avibactam against Gram-negative Bacteria Isolated from Patients Hospitalized with Pneumonia in Europe, Latin America, and Asia in 2019
por: Sader, Helio S, et al.
Publicado: (2020)

1629. Vancomycin Resistance in Enterococcus faecium Clinical Isolates Responsible for Bloodstream Infections in US Hospitals Over Ten Years (2010-2019) and Activity of Oritavancin
por: Carvalhaes, Cecilia G, et al.
Publicado: (2020)

1148. Activity of Posaconazole and Comparator Antifungal agents Tested Against Filamentous Fungi
por: Castanheira, Mariana, et al.
Publicado: (2020)

MicroRNA-1258: An invasion and metastasis regulator that targets heparanase in gastric cancer
por: Shi, Jinxin, et al.
Publicado: (2021)

1229. Antimicrobial Activity of Plazomicin against Multidrug-resistant Enterobacterales: Results from 3 Years of Surveillance in Hospitals in the United States (2018–2020)
por: Carvalhaes, Cecilia G, et al.
Publicado: (2021)

1278. Impact of Different Breakpoint Criteria on the Susceptibility Rates of Enterobacterales resistant Subsets to the Aminoglycosides
por: Sader, Helio S, et al.
Publicado: (2020)

P1258: MOLECULAR CYTOGENETICS CHARACTERIZATION OF CLASSICAL HODGKIN LYMPHOMA. ROL OF 9P24.1 (PD-L1/PD-L2) POLYSOMIES
por: García-Montenegro, M., et al.
Publicado: (2022)

1472. Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria Isolated from Patients Hospitalized with Bacterial Pneumonia in the United States, Western Europe, and Eastern Europe: Results from the SENTRY Program (2016-2019)
por: Sader, Helio S, et al.
Publicado: (2020)

P1258: A CO-REACTIVATION MODEL OF DOUBLE-STRANDED DNA VIRUS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WAS CONSTRUCTED TO PREDICT THE MORTALITY AFTER TRANSPLANTATION
por: Ren, Jinhua, et al.
Publicado: (2023)

Research progress on microRNA-1258 in the development of human cancer
por: Qian, Mengjia, et al.
Publicado: (2022)

1253. In Vitro Activity of Omadacycline against 7000 Bacterial Pathogens from the United States Stratified by Infection Type (2019)
por: Huband, Michael D, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4juac60iv0b3t4hbqc0mujnslo